Stability of the tumor suppressor merlin depends on its ability to bind paxillin LD3 and associate with β1 integrin and actin at the plasma membrane

Biology Open

Volumn 1, Issue 10, 2012, Pages 949-957

  Manetti, Maria Elisa ^a   Geden, Sandra ^a   Bott, Marga ^a   Sparrow, Nicklaus ^a   Lambert, Stephen ^a   Fernandez Valle, Cristina ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Actin; LD domain; Merlin; NF2; Paxillin; Schwann cells; 1 integrin

Indexed keywords

EID: 84964902871     PISSN: None     EISSN: 20466390     Source Type: Journal    
DOI: 10.1242/bio.20122121     Document Type: Article

References (42)

1. Ahronowitz, I., Xin, W., Kiely, R., Sims, K., MacCollin, M. and Nunes, F. P. (2007). Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings. Hum. Mutat. 28, 1-12.
2. Alfthan, K., Heiska, L., Grönholm, M., Renkema, G. H. and Carpén, O. (2004). Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization. J. Biol. Chem. 279, 18559-18566.
3. Altschul, S. F., Madden, T. L., Schäffer, A. A., Zhang, J., Zhang, Z., Miller, W. and Lipman, D. J. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25, 3389-3402.
4. Brault, E., Gautreau, A., Lamarine, M., Callebaut, I., Thomas, G. and Goutebroze, L. (2001). Normal membrane localization and actin association of the NF2 tumor suppressor protein are dependent on folding of its N-terminal domain. J. Cell Sci. 114, 1901-1912.
5. Bretscher, A., Edwards, K. and Fehon, R. G. (2002). ERM proteins and merlin: integrators at the cell cortex. Nat. Rev. Mol. Cell Biol. 3, 586-599.
6. Brown, M. C. and Turner, C. E. (2004). Paxillin: adapting to change. Physiol. Rev. 84, 1315-1339.
7. Brown, M. C., Curtis, M. S. and Turner, C. E. (1998). Paxillin LD motifs may define a new family of protein recognition domains. Nat. Struct. Biol. 5, 677-678.
8. Chernousov, M. A., Yu, W. M., Chen, Z. L., Carey, D. J. and Strickland, S. (2008). Regulation of Schwann cell function by the extracellular matrix. Glia 56, 1498-1507.
9. Deguen, B., Mérel, P., Goutebroze, L., Giovannini, M., Reggio, H., Arpin, M. and Thomas, G. (1998). Impaired interaction of naturally occurring mutant NF2 protein with actin-based cytoskeleton and membrane. Hum. Mol. Genet. 7, 217-226.
10. Fernandez-Valle, C., Tang, Y., Ricard, J., Rodenas-Ruano, A., Taylor, A., Hackler, E., Biggerstaff, J. and Iacovelli, J. (2002). Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat. Genet. 31, 354-362.
11. Gautreau, A., Manent, J., Fievet, B., Louvard, D., Giovannini, M. and Arpin, M. (2002). Mutant products of the NF2 tumor suppressor gene are degraded by the ubiquitin-proteasome pathway. J. Biol. Chem. 277, 31279-31282.
12. Giovannini, M., Robanus-Maandag, E., van der Valk, M., Niwa-Kawakita, M., Abramowski, V., Goutebroze, L., Woodruff, J. M., Berns, A. and Thomas, G. (2000). Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 14, 1617-1630.
13. Gonzalez-Agosti, C., Xu, L., Pinney, D., Beauchamp, R., Hobbs, W., Gusella, J. and Ramesh, V. (1996). The merlin tumor suppressor localizes preferentially in membrane ruffles. Oncogene 13, 1239-1247.
14. Goujon, M., McWilliam, H., Li, W., Valentin, F., Squizzato, S., Paern, J. and Lopez, R. (2010). A new bioinformatics analysis tools framework at EMBL-EBI. Nucleic Acids Res. 38, Suppl 2 W695-W699.
15. Grönholm, M., Sainio, M., Zhao, F., Heiska, L., Vaheri, A. and Carpén, O. (1999). Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin. J. Cell Sci. 112, 895-904.
16. Guex, N. and Peitsch, M. C. (1997). SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18, 2714-2723.
17. Gutmann, D. H., Haipek, C. A. and Hoang Lu, K. (1999). Neurofibromatosis 2 tumor suppressor protein, merlin, forms two functionally important intramolecular associations. J. Neurosci. Res. 58, 706-716.
18. Hoellerer, M. K., Noble, M. E., Labesse, G., Campbell, I. D., Werner, J. M. and Arold, S. T. (2003). Molecular recognition of paxillin LD motifs by the focal adhesion targeting domain. Structure 11, 1207-1217.
19. Kang, B. S., Cooper, D. R., Devedjiev, Y., Derewenda, U. and Derewenda, Z. S. (2002). The structure of the FERM domain of merlin, the neurofibromatosis type 2 gene product. Acta Crystallogr. D Biol. Crystallogr. 58, 381-391.
20. Kisselev, A. F. and Goldberg, A. L. (2001). Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 8, 739-758.
21. Kissil, J. L., Johnson, K. C., Eckman, M. S. and Jacks, T. (2002). Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J. Biol. Chem. 277, 10394-10399.
22. Lallemand, D., Manent, J., Couvelard, A., Watilliaux, A., Siena, M., Chareyre, F., Lampin, A., Niwa-Kawakita, M., Kalamarides, M. and Giovannini, M. (2009a). Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene 28, 854-865.
23. Lallemand, D., Saint-Amaux, A. L. and Giovannini, M. (2009b). Tumor-suppression functions of merlin are independent of its role as an organizer of the actin cytoskeleton in Schwann cells. J. Cell Sci. 122, 4141-4149.
24. Larkin, M. A., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P. A., McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., Lopez, R. et al. (2007). Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947-2948.
25. Li, W., You, L., Cooper, J., Schiavon, G., Pepe-Caprio, A., Zhou, L., Ishii, R., Giovannini, M., Hanemann, C. O., Long, S. B. et al. (2010). Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 140, 477-490.
26. Maitra, S., Kulikauskas, R. M., Gavilan, H. and Fehon, R. G. (2006). The tumor suppressors Merlin and Expanded function cooperatively to modulate receptor endocytosis and signaling. Curr. Biol. 16, 702-709.
27. Morrison, H., Sherman, L. S., Legg, J., Banine, F., Isacke, C., Haipek, C. A., Gutmann, D. H., Ponta, H. and Herrlich, P. (2001). The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 15, 968-980.
28. Obremski, V. J., Hall, A. M. and Fernandez-Valle, C. (1998). Merlin, the neurofibromatosis type 2 gene product, and beta1 integrin associate in isolated and differentiating Schwann cells. J. Neurobiol. 37, 487-501.
29. Plopper, G. and Ingber, D. E. (1993). Rapid induction and isolation of focal adhesion complexes. Biochem. Biophys. Res. Commun. 193, 571-578.
30. Robertson, L. K. and Ostergaard, H. L. (2011). Paxillin associates with the microtubule cytoskeleton and the immunological synapse of CTL through its leucineaspartic acid domains and contributes to microtubule organizing center reorientation. J. Immunol. 187, 5824-5833.
31. Rouleau, G. A., Merel, P., Lutchman, M., Sanson, M., Zucman, J., Marineau, C., Hoang-Xuan, K., Demczuk, S., Desmaze, C., Plougastel, B. et al. (1993). Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 363, 515-521.
32. Schaller, M. D. (2001). Paxillin: a focal adhesion-associated adaptor protein. Oncogene 20, 6459-6472.
33. Scoles, D. R., Huynh, D. P., Morcos, P. A., Coulsell, E. R., Robinson, N. G., Tamanoi, F. and Pulst, S. M. (1998). Neurofibromatosis 2 tumour suppressor schwannomin interacts with betaII-spectrin. Nat. Genet. 18, 354-359.
34. Taylor, A. R., Geden, S. E. and Fernandez-Valle, C. (2003). Formation of a beta1 integrin signaling complex in Schwann cells is independent of rho. Glia 41, 94-104.
35. Thaxton, C., Lopera, J., Bott, M. and Fernandez-Valle, C. (2008). Neuregulin and laminin stimulate phosphorylation of the NF2 tumor suppressor in Schwann cells by distinct protein kinase A and p21-activated kinase-dependent pathways. Oncogene 27, 2705-2715.
36. Trofatter, J. A., MacCollin, M. M., Rutter, J. L., Murrell, J. R., Duyao, M. P., Parry, D. M., Eldridge, R., Kley, N., Menon, A. G., Pulaski, K. et al. (1993). A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72, 791-800.
37. Tumbarello, D. A., Brown, M. C. and Turner, C. E. (2002). The paxillin LD motifs. FEBS Lett. 513, 114-118.
38. Turner, C. E. (2000). Paxillin interactions. J. Cell Sci. 113, 4139-4140.
39. Turner, C. E., Glenney, J. R., Jr and Burridge, K. (1990). Paxillin: a new vinculinbinding protein present in focal adhesions. J. Cell Biol. 111, 1059-1068.
40. Turner, C. E., Brown, M. C., Perrotta, J. A., Riedy, M. C., Nikolopoulos, S. N., McDonald, A. R., Bagrodia, S., Thomas, S. and Leventhal, P. S. (1999). Paxillin LD4 motif binds PAK and PIX through a novel 95-kD ankyrin repeat, ARF-GAP protein: A role in cytoskeletal remodeling. J. Cell Biol. 145, 851-863.
41. Xiao, G. H., Beeser, A., Chernoff, J. and Testa, J. R. (2002). p21-activated kinase links Rac/Cdc42 signaling to merlin. J. Biol. Chem. 277, 883-886.
42. Yogesha, S. D., Sharff, A. J., Giovannini, M., Bricogne, G. and Izard, T. (2011). Unfurling of the band 4.1, ezrin, radixin, moesin (FERM) domain of the merlin tumor suppressor. Protein Sci. 20, 2113-2120.